Clinical trial · Observational
Prevelance Of Cutaneous Disorders Among Patients With Heamatologic Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hematologic malignancies are a diverse group of neoplasms that can have a wide range of clinical and behavioral characteristics. Infections are also a common complication of hematologic malignancies, and can manifest as cutaneous eruptions. Hair loss is a common symptom of hematological malignancies. Changes in the nails can also occur in patients with hematological malignancies. Chemotherapy and radiotherapy are two common treatments for hematological malignancies. patients may experience a wide range of side effects, including hair loss, changes in the nails, and mucositis (
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dermatologic Disorders With Heamatologic Malignancies Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cbc ,u\s renalor hepatic function test if needed | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Prevelance Of Cutaneous Disordera Amog Patients with Heamatologic Malignancies
- timeFrame
- 1 year
- description
- \- A cross - sectional study will include patients who attending and/or admitted to Clinical Oncology and Nuclear Medicine Department Sohag university Hospital.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Age: all age groups. * Sex: both sex will be included. * Patients with confirmed diagnosis of haematological malignancies ethier clinically or laboratory. Exclusion Criteria: * Pregnancy., • Patients with medical comorbidities (liver ,renal ,thyroid abnormalities ,other malignancies)
References
Publications (4)
- BACKGROUNDAtkins S, He F. Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies. Infect Dis Clin North Am. 2019 Jun;33(2):289-309. doi: 10.1016/j.idc.2019.01.001. Epub 2019 Mar 30. PMID 30935703
- BACKGROUNDDidona D, Fania L, Didona B, Eming R, Hertl M, Di Zenzo G. Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis. Int J Mol Sci. 2020 Mar 21;21(6):2178. doi: 10.3390/ijms21062178. PMID 32245283
- BACKGROUNDDika E, Patrizi A, Veronesi G, Manuelpillai N, Lambertini M. Malignant cutaneous tumours of the scalp: always remember to examine the head. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2208-2215. doi: 10.1111/jdv.16330. Epub 2020 Apr 7. PMID 32119157
- BACKGROUNDLiu YQ, Wang XL, He DH, Cheng YX. Protection against chemotherapy- and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals. Phytomedicine. 2021 Jan;80:153402. doi: 10.1016/j.phymed.2020.153402. Epub 2020 Oct 31. PMID 33203590